Antiangiogenic effectiveness of the urokinase receptor- derived peptide UPARANT in a model of oxygen-induced retinopathy

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 4, 2015, Pages 2392-2407

  Dal Monte, Massimo ^a   Rezzola, Sara ^b   Cammalleri, Maurizio ^a   Belleri, Mirella ^b   Locri, Filippo ^a   Morbidelli, Lucia ^c   Corsini, Michela ^b   Paganini, Giuseppe ^b   Semeraro, Francesco ^b   Cancarini, Anna ^b   Rusciano, Dario ^d   Presta, Marco ^b   Bagnoli, Paola ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d Sooft Italia Spa   (Italy)

Author keywords

PDR vitreous fluid; Retina; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BROMETHOL; CD31 ANTIGEN; COMPLEMENTARY DNA; GLIAL FIBRILLARY ACIDIC PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; OCCLUDIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UPARANT; UROKINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; ACETYL-ARGINYL-AMINOISOBUTYRYL-ARGINYL-C(ALPHA)-METHYLPHENYLALANINAMIDE; OLIGOPEPTIDE; OXYGEN;

ANGIOGENESIS ASSAY; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD RETINA BARRIER; CONTROLLED STUDY; DENSITOMETRY; ELECTRORETINOGRAPHY; FEMALE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; MALE; MOUSE; NONHUMAN; OSCILLATORY POTENTIAL; OXYGEN-INDUCED RETINOPATHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RETINA EXAMINATION; RETINA NEOVASCULARIZATION; RETINITIS; RNA ISOLATION; TUNEL ASSAY; UMBILICAL VEIN ENDOTHELIAL CELL; VISION; VISUAL IMPAIRMENT; WESTERN BLOTTING; ANIMAL; CHEMICALLY INDUCED; CHICK EMBRYO; DISEASE MODEL; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; RETINAL DISEASES;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOOD-RETINAL BARRIER; BLOTTING, WESTERN; CHICK EMBRYO; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MICE; OLIGOPEPTIDES; OXYGEN; RETINAL DISEASES;

EID: 84934904620     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.14-16323     Document Type: Article

References (83)

1. Montuori N, Ragno P. Role of uPA/uPAR in the modulation of angiogenesis. Chem Immunol Allergy. 2014;99:105-122.
2. Uhrin P, Breuss JM. uPAR: a modulator of VEGF-induced angiogenesis. Cell Adh Migr. 2013;7:23-26.
3. Binder BR, Mihaly J, Prager GW. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view. Thromb Haemost. 2007;97:336-342.
4. Bifulco K, Longanesi-Cattani I, Gala M, et al. The soluble form of urokinase receptor promotes angiogenesis through its Ser88-Arg-Ser-Arg-Tyr92 chemotactic sequence. J Thromb Haemost. 2010;8:2789-2799.
5. Ramsey DJ, Haddock LJ, Young LH, Eliott D. Complications of subspecialty ophthalmic care: systemic complications from the intravitreal administration of agents that target the vascular endothelial growth factor pathway. Semin Ophthalmol. 2014; 29:263-275.
6. Fleck BW. Management of retinopathy of prematurity. Arch Dis Child Fetal Neonatal Ed. 2013;98:F454-F456.
7. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis. 2007; 10:141-148.
8. McGuire PG, Jones TR, Talarico N, Warren E, Das A. The urokinase/urokinase receptor system in retinal neovascular-ization: inhibition by A6 suggests a new therapeutic target. Invest Ophthalmol Vis Sci. 2003;44:2736-2742.
9. Colombo ES, Menicucci G, McGuire PG, Das A. Hepatocyte growth factor/scatter factor promotes retinal angiogenesis through increased urokinase expression. Invest Ophthalmol Vis Sci. 2007;48:1793-1800.
10. Sugioka K, Kodama A, Okada K, et al. TGF-P2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression. Exp Eye Res. 2013; 115:13-21.
11. Navaratna D, Menicucci G, Maestas J, Srinivasan R, McGuire P, Das A. A peptide inhibitor ofthe urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes. FASEB J. 2008;22:3310-3317.
12. Das A, Boyd N, Jones TR, Talarico N, McGuire PG. Inhibition of choroidal neovascularization by a peptide inhibitor of the urokinase plasminogen activator and receptor system in a mouse model. Arch Ophthalmol. 2004;122:1844-1849.
13. Carriero MV, Bifulco K, Minopoli M, et al. UPARANT: a urokinase receptor-derived peptide inhibitor of VEGF-driven angiogenesis with enhanced stability and in vitro and in vivo potency. Mol Cancer Ther. 2014;13:1092-1104.
14. Malla RR, Gopinath S, Gondi CS, et al. Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther. 2011;18: 419-434.
15. Ahmad A, Kong D, Sarkar SH, Wang Z, Banerjee S, Sarkar FH. Inactivation of uPA and its receptor uPAR by 3,3 -diindolyl-methane (DIM) leads to the inhibition of prostate cancer cell growth and migration. JCell Biochem. 2009;107:516-527.
16. Nalabothula N, Lakka SS, Dinh DH, Guirati M, Olivero WC, Rao JS. Sense p16 and antisense uPAR bicistronic construct inhibits angiogenesis and induces glioma cell death. Int JOncol. 2007; 30:669-678.
17. Grossniklaus HE, Kang SJ, Berglin L. Animal models of choroidal and retinal neovascularization. Prog Retin Eye Res. 2010;29:500-519.
18. Stahl A, Connor KM, Sapieha P, et al. The mouse retina as an angiogenesis model. Invest Ophthalmol Vis Sci. 2010;51: 2813-2826.
19. Scott A, Fruttiger M. Oxygen-induced retinopathy: a model for vascular pathology in the retina. Eye (Lond). 2010;24:416-421.
20. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res. 2008;27:622-647.
21. Sapieha P, Chen J, Stahl A, et al. Omega-3 polyunsaturated fatty acids preserve retinal function in type 2 diabetic mice. Nutr Diabetes. 2012;2:e36.
22. Stahl A, Chen J, Sapieha P, et al. Postnatal weight gain modifies severity and functional outcome of oxygen-induced prolifera-tive retinopathy. Am J Pathol. 2010;177:2715-2723.
23. Fulton AB, Hansen RM, Moskowitz A, Akula JD. The neurovascular retina in retinopathy ofprematurity. ProgRetin Eye Res. 2009;28:452-482.
24. Fulton AB, Akula JD, Mocko JA, et al. Retinal degenerative and hypoxic ischemic disease. Doc Ophthalmol. 2009;118:55-61.
25. Rezzola S, Belleri M, Ribatti D, Costagliola C, Presta M, Semeraro F. A novel ex vivo murine retina angiogenesis (EMRA) assay. Exp Eye Res. 2013;112:51-56.
26. Shirasawa M, Arimura N, Otsuka H, Sonoda S, Hashiguchi T, Sakamoto T. Intravitreous VEGF-A in eyes with massive vitreous hemorrhage. Graefes Arch Clin Exp Ophthalmol. 2011;249:1805-1810.
27. Merlak M, Kovacevic D, Balog T, et al. Expression of vascular endothelial growth factor in proliferative diabetic retinopathy. Coll Antropol. 2008;32(suppl 2):39-43.
28. Simo R, Carrasco E, Garcia-Ramfrez M, Hernandez C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71-98.
29. Yang J, Klassen H, Pries M, Wang W, Nissen MH. Vitreous humor and albumin augment the proliferation of cultured retinal precursor cells. JNeurosci Res. 2009;87:495-502.
30. Takagi H, Watanabe D, Suzuma K, et al. Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2007;77(suppl 1):S62-S64.
31. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl JMed. 2005;353:782-792.
32. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl JMed. 1994; 331:1480-1487.
33. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35: 101-111.
34. Favaloro EJ, Moraitis N, Koutts J, Exner T, Bradstock KF. Endothelial cells and normal circulating haemopoietic cells share a number of surface antigens. Thromb Haemost. 1989; 61:217-224.
35. Dal Monte M, Casini G, la Marca G, Isacchi B, Filippi L, Bagnoli P. Eye drop propranolol administration promotes the recovery of oxygen-induced retinopathy in mice. Exp Eye Res. 2013; 111:27-35.
36. Dal Monte M, Martini D, Latina V, Pavan B, Filippi L, Bagnoli P. Beta-adrenoreceptor agonism influences retinal responses to hypoxia in a model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2012;53:2181-2192.
37. Martini D, Dal Monte M, Ristori C, et al. Antiangiogenic effects of b(2)-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy. J Neurochem. 2011;119:1317-1329.
38. Banin E, Dorrell MI, Aguilar E, et al. T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci. 2006;47:2125-2134.
39. Berkowitz BA, Roberts R, Luan H, Peysakhov J, Mao X, Thomas KA. Dynamic contrast-enhanced MRI measurements of passive permeability through blood retinal barrier in diabetic rats. Invest Ophthalmol Vis Sci. 2004;45:2391-2398.
40. Trichonas G, Manola A, Morizane Y, et al. A novel nonradio-active method to evaluate vascular barrier breakdown and leakage. Invest Ophthalmol Vis Sci. 2010;51:1677-1682.
41. Dal Monte M, Latina V, Cupisti E, Bagnoli P. Protective role of somatostatin receptor 2 against retinal degeneration in response to hypoxia. Naunyn Schmiedebergs Arch Pharmacol. 2012;385:481-494.
42. Robson JG, Saszik SM, Ahmed J, Frishman LJ. Rod and cone contributions to the a-wave of the electroretinogram of the macaque. JPhysiol. 2003;547:509-530.
43. Vessey KA, Wilkinson-Berka JL, Fletcher EL. Characterization of retinal function and glial cell response in a mouse model of oxygen induced retinopathy. J Comp Neurol. 2011;519:506-527.
44. Bresnick GH, Palta M. Oscillatory potential amplitudes. Relation to severity of diabetic retinopathy. Arch Ophthalmol. 1987;105;929-933.
45. Hombrebueno JR, Luo C, Guo L, Chen M, Xu H. Intravitreal injection of normal saline induces retinal degeneration in the C57BL/6J mouse. Transl Vis Sci Technol. 2014;3(2):3.
46. Elsherbiny NM, Ahmad S, Naime M, et al. ABT-702, an adenosine kinase inhibitor, attenuates inflammation in diabetic retinopathy. Life Sci. 2013;93:78-88.
47. Wang X, Seed BA. PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 2003;31:e154.
48. Pattyn F, Speleman F, De Paepe A, Vandesompele J. RTPri-merDB: the real-time PCR primer and probe database. Nucleic Acids Res. 2003;31:122-123.
49. Mazumder B, Sampath P, Seshadri V, Maitra RK, DiCorleto PE, Fox PL. Regulated release of L13a from the 60S ribosomal subunit as a mechanism of transcript-specific translational control. Cell. 2003;115:187-198.
50. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(—Delta Delta C(T)) method. Methods. 2001;25:402-408.
51. Stabile H, Mitola S, Moroni E, et al. Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. Blood. 2007;109:1834-1840.
52. Mitola S, Moroni E, Ravelli C, Andres G, Belleri M, Presta M. Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm. Blood. 2008;112: 1154-1157.
53. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-371.
54. Antonetti DA, Barber AJ, Khin S, Lieth E, Tarbell JM, Gardner TW. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998;47:1953-1959.
55. Vinores SA, Derevjanik NL, Ozaki H, Okamoto N, Campo-chiaro PA. Cellular mechanisms of blood-retinal barrier dysfunction in macular edema. Doc Ophthalmol. 1999;97: 217-228.
56. Ristori C, Filippi L, Dal Monte M, et al. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. 2011;52:155-170.
57. Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates retinal apoptosis in ischemic proliferative retinopathy. JNeurosci. 2002;22:3987-3993.
58. Liang X, Zhou H, Ding Y, et al. TMP prevents retinal neovascularization and imparts neuroprotection in an oxygen-induced retinopathy model. Invest Ophthalmol Vis Sci. 2012;53:2157-2169.
59. Kaur C, Rathnasamy G, Ling EA. Roles of activated microglia in hypoxia induced neuroinflammation in the developing brain and the retina. JNeuroimmune Pharmacol. 2013;8:66-78.
60. Wang M, Ma W, Zhao L, Fariss RN, Wong WT. Adaptive Muller cell responses to microglial activation mediate neuroprotec-tion and coordinate inflammation in the retina. J Neuroinflammation. 2011;8:173.
61. Staton CA, Reed MW, Brown NJ. Acritical analysis ofcurrentin vitro and in vivo angiogenesis assays. Int JExp Pathol. 2009; 90:195-221.
62. Vlieghe P, Lisowski V, Martinez J, Khrestchatisky M. Synthetic therapeutic peptides: science and market. Drug Discov Today. 2010;15:40-56.
63. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58:1131-1135.
64. Bai Y, Zhao M, Zhang C, et al. Anti-angiogenic effects of a mutant endostatin: a new prospect for treating retinal and choroidal neovascularization. PLoS One. 2014;9:e112448.
65. Poettler M, Unseld M, Mihaly-Bison J. The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration. Thromb Haemost. 2012;108:357-366.
66. Le Gat L, Gogat K, Bouquet C, et al. In vivo adenovirus-mediated delivery of a uPA/uPAR antagonist reduces retinal neovascularization in a mouse model of retinopathy. Gene Ther. 2003;10:2098-2103.
67. Muthusamy A, Lin CM, Shanmugam S, Lindner HM, Abcouwer SF, Antonetti DA. Ischemia-reperfusion injury induces occludin phosphorylation/ubiquitination and retinal vascular permeability in a VEGFR-2-dependent manner. JCereb Blood Flow Metab. 2014;34:522-531.
68. Larusch GA, Merkulova A, Mahdi F, et al. Domain 2 of uPAR regulates single-chain urokinase-mediated angiogenesis through b1-integrin and VEGFR2. Am J Physiol Heart Circ Physiol. 2013;305:H305-H320.
69. Fong GH. Regulation of angiogenesis by oxygen sensing mechanisms. JMol Med. 2009;87:549-560.
70. Chen Z, Han ZC. STAT3: a critical transcription activator in angiogenesis. Med Res Rev. 2008;28:185-200.
71. Oellerich T, Oellerich MF, Engelke M, et al. b2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk/STAT signaling axis. Blood. 2013;121:3889-3899.
72. El-Remessy AB, Franklin T, Ghaley N, et al. Diabetes-induced superoxide anion and breakdown of the blood-retinal barrier: role of the VEGF/uPAR pathway. PLoS One. 2013;8:e71868.
73. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol. 2003;162:1995-2004.
74. Downie LE, Pianta MJ, Vingrys AJ, Wilkinson-Berka JL, Fletcher EL. Neuronal and glial cell changes are determined by retinal vascularization in retinopathy of prematurity. JComp Neurol. 2007;504:404-417.
75. Akula JD, Hansen RM, Martinez-Perez ME, Fulton AB. Rod photoreceptor function predicts blood vessel abnormality in retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2007; 48:4351-4359.
76. Akula JD, Hansen RM, Tzekov R, et al. Visual cycle modulation in neurovascular retinopathy. Exp Eye Res. 2010;91:153-161.
77. Hatzopoulos KM, Vessey KA, Wilkinson-Berka JL, Fletcher EL. The vasoneuronal effects of AT1 receptor blockade in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2014;55:3957-3970.
78. Gaucher D, Chiappore JA, Paques M. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res. 2007;47:612-623.
79. Reichenbach A, Wurm A, Pannicke T, Iandiev I, Wiedemann P, Bringmann A. Muller cells as players in retinal degeneration and edema. Graefes Arch Clin Exp Ophthalmol. 2007;245: 627-636.
80. Newman EA. Muller cells and the retinal pigment epithelium. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. Philadelphia: Saunders; 2000:1763-1785.
81. Ishizuka F, Shimazawa M, Egashira Y, et al. Cilostazol prevents retinal ischemic damage partly via inhibition of tumor necrosis factor-a-induced nuclear factor-kappa B/activator protein-1 signaling pathway. Pharmacol Res Perspect. 2013;1:e00006.
82. Abcouwer SF, Gardner TW. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Ann N YAcad Sci. 2014;1311:174-190.
83. Garcia C, Aranda J, Arnold E, et al. Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation. J Clin Invest. 2008;118:2291-2300.